Literature DB >> 17041799

New ambulatory implant technique of high-dose-rate interstitial brachytherapy for prostate cancer.

Ken Yoshida1, Takayuki Nose, Hiroya Shiomi, Yasuo Yoshioka, Yuka Fujita, Satoru Kuroda, Mineo Yoshida, Tohru Takahashi, Masaya Kitamura, Hideyuki Akai, Toshitsugu Oka, Takuya Hosoki.   

Abstract

PURPOSE: The aim of this study was to improve the performance status of prostate cancer patients during high-dose-rate interstitial brachytherapy (HDR-ISBT). To this end, we have developed a new ambulatory implant technique.
MATERIALS AND METHODS: Ten prostate cancer patients were treated with HDR-ISBT as monotherapy from October 2003 until March 2004. We utilized a new removable template, a flexible applicator with a nonmetallic bead and button stopper, and an inner catheter connecting the applicator and the transfer tube of the brachytherapy unit. We shortened the connector end of the flexible applicator to enable the patient to sit down and walk freely during the treatment time.
RESULTS: All 10 patients could walk without any support. No problem in the application was observed.
CONCLUSION: Our new ambulatory implant technique for HDR-ISBT was able to improve the performance status of prostate cancer patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17041799     DOI: 10.1007/s11604-007-0058-1

Source DB:  PubMed          Journal:  Radiat Med        ISSN: 0288-2043


  8 in total

1.  The prospects for new treatments for prostate cancer.

Authors:  Jack F Fowler; Rick J Chappell; Mark A Ritter
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-01-01       Impact factor: 7.038

2.  High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: treatment description and preliminary results of a phase I/II clinical trial.

Authors:  Y Yoshioka; T Nose; K Yoshida; T Inoue; H Yamazaki; E Tanaka; H Shiomi; A Imai; S Nakamura; S Shimamoto; T Inoue
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-10-01       Impact factor: 7.038

3.  Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: a feasibility report.

Authors:  A A Martinez; I Pataki; G Edmundson; E Sebastian; D Brabbins; G Gustafson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-01-01       Impact factor: 7.038

4.  Feasibility study combining low dose rate (192)Ir brachytherapy and external beam radiotherapy aiming at delivering 80-85 Gy to prostatic adenocarcinoma.

Authors:  P Nickers; L Coppers; M Beauduin; M Darimont; J de Leval; J Deneufbourg
Journal:  Radiother Oncol       Date:  2000-04       Impact factor: 6.280

5.  Needle displacement during HDR brachytherapy in the treatment of prostate cancer.

Authors:  S J Damore; A M Syed; A A Puthawala; A Sharma
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-03-15       Impact factor: 7.038

6.  Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue.

Authors:  David J Brenner; Alvaro A Martinez; Gregory K Edmundson; Christina Mitchell; Howard D Thames; Elwood P Armour
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-01-01       Impact factor: 7.038

7.  High-dose-rate brachytherapy as monotherapy for localized prostate cancer: a retrospective analysis with special focus on tolerance and chronic toxicity.

Authors:  Yasuo Yoshioka; Takayuki Nose; Ken Yoshida; Ryoong Jin Oh; Yuji Yamada; Eiichi Tanaka; Hideya Yamazaki; Takehiro Inoue; Toshihiko Inoue
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-05-01       Impact factor: 7.038

8.  Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer.

Authors:  Junichi Hiratsuka; Yoshimasa Jo; Kenji Yoshida; Naomi Nagase; Masato Fujisawa; Yoshinari Imajo
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-07-01       Impact factor: 7.038

  8 in total
  5 in total

Review 1.  Current status and perspectives of brachytherapy for prostate cancer.

Authors:  Yasuo Yoshioka
Journal:  Int J Clin Oncol       Date:  2009-02-20       Impact factor: 3.402

2.  High-dose-rate interstitial brachytherapy in combination with androgen deprivation therapy for prostate cancer: are high-risk patients good candidates?

Authors:  Ken Yoshida; Hideya Yamazaki; Tadashi Takenaka; Tadayuki Kotsuma; Mineo Yoshida; Koji Masui; Yasuo Yoshioka; Yoshifumi Narumi; Toshitsugu Oka; Eiichi Tanaka
Journal:  Strahlenther Onkol       Date:  2014-05-17       Impact factor: 3.621

Review 3.  High-dose-rate brachytherapy as monotherapy for prostate cancer: technique, rationale and perspective.

Authors:  Yasuo Yoshioka; Osamu Suzuki; Yuki Otani; Ken Yoshida; Takayuki Nose; Kazuhiko Ogawa
Journal:  J Contemp Brachytherapy       Date:  2014-04-03

4.  High-dose-rate interstitial brachytherapy with hypoxic radiosensitizer KORTUC II for unresectable pelvic sidewall recurrence of uterine cervical cancer: a case report.

Authors:  Mio Nakata; Ken Yoshida; Taiju Shimbo; Nobuhiko Yoshikawa; Hiroto Yoshioka; Akihiro Hori; Chikara Sato; Yasuo Uesugi; Yuhei Kogata; Koji Masui; Naoya Murakami; Tairo Kashihara; Hironori Akiyama; Nikolaos Tselis; Masahide Ohmichi; Keiji Nihei
Journal:  J Contemp Brachytherapy       Date:  2020-12-16

5.  3D-Image-Guided Multi-Catheter Interstitial Brachytherapy for Bulky and High-Risk Stage IIB-IVB Cervical Cancer.

Authors:  Tetsuya Kokabu; Koji Masui; Yosuke Tarumi; Naoki Noguchi; Kohei Aoyama; Hisashi Kataoka; Hiroshi Matsushima; Kaori Yoriki; Daisuke Shimizu; Hideya Yamazaki; Kei Yamada; Taisuke Mori
Journal:  Cancers (Basel)       Date:  2022-02-28       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.